ArticleFrontiers in pharmacology2025
Comparative effectiveness and pharmacological fingerprints of indobufen versus rivaroxaban in patients with chronic kidney disease: a single-center, real-world study.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Antithrombotic management in Chronic Kidney Disease (CKD) is a clinical dilemma. This study aimed to empirically evaluate the " Methods: In this retrospective cohort study (2020-2024), we analyzed CKD patients treated with indobufen or rivaroxaban. A multi-stage analysis first used machine learning to assess baseline cohort comparability, overcoming limitations of p-value-based tests. Subsequently, a Linear Mixed Model (LMM), adjusted for confounders including polypharmacy, assessed independent drug effects on in-hospital thrombosis, hemorrhage, and longitudinal laboratory markers. Results: Machine learning demonstrated the clinical comparability of the indobufen and rivaroxaban cohorts. The incidence of in-hospital thrombosis was numerically lower in the indobufen group (3.65% vs. 7.58%; Conclusion: In this real-world CKD cohort, indobufen and rivaroxaban demonstrated comparable clinical effectiveness and safety. Combining machine learning with longitudinal models helps to statistically adjust for complex confounders like polypharmacy, thereby providing a more robust estimate of a drug's independent effect.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.